Peter Altman, President and CEO of BioCardia, Inc. (NASDAQ:BCDA), acquired 5,700 shares of the company's common stock on May 18, 2026. The total value of this transaction amounted to $5,244.
The shares were purchased at a weighted average price of $0.92 per share. According to the filing, these transactions occurred in multiple trades with prices ranging from $0.89 to $1.02 per share. The timing of this insider purchase is notable as the stock is trading near its 52-week low of $0.84 and has declined 59% over the past year.
Following this acquisition, Mr. Altman directly owns 291,566 shares of BioCardia common stock. According to Bond.az analysis, the stock appears undervalued based on its Fair Value assessment.
In other recent news, BioCardia Inc. reported its first-quarter 2026 earnings, highlighting significant operational improvements and strategic clinical advancements. The company is focused on reducing expenses while advancing its CardiAMP cell therapy program. BioCardia currently holds a cash position of $951,000 and plans to secure additional funding.
